SCHEMBL3595324

SCHEMBL3595324

CN(CCNC(=O)Cn1ccc2cccc(-c3cccc(C#N)c3)c21)C1CCCCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.42
KDM4E B2RXH2 4/20 0.42
ALDH1A1 P00352 4/20 0.42
HSD17B10 Q99714 3/20 0.42
HPGD P15428 3/20 0.42
USP2 O75604 1/20 0.42
POLB P06746 1/20 0.42
GAA P10253 1/20 0.39
MCOLN3 Q8TDD5 1/20 0.38
CHRM3 P20309 1/20 0.37
GLA P06280 1/20 0.37
HTT P42858 1/20 0.37
KCNJ6 P48051 1/20 0.36
KCNJ5 P48544 1/20 0.36
KCNJ3 P48549 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ITK Q08881 1/20 0.36
MCHR1 Q99705 1/20 0.35
MAPT P10636 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3597285 0.88 MAPT (0.46) TSHRKDM4EALDH1A1HSD17B10HPGD
SCHEMBL3605991 0.87 GAA (0.44) TSHRKDM4EALDH1A1HSD17B10HPGD
SCHEMBL3597443 0.86 KDM4E (0.42) TSHRKDM4EALDH1A1HSD17B10POLB
SCHEMBL3602560 0.86 ALDH1A1 (0.53) TSHRKDM4EALDH1A1HSD17B10HPGD
SCHEMBL3589634 0.85 GAA (0.38) TSHRKDM4EALDH1A1HSD17B10HPGD
SCHEMBL3594706 0.85 GAA (0.42) TSHRKDM4EALDH1A1HSD17B10HPGD
SCHEMBL3592315 0.84 GAA (0.42) TSHRKDM4EALDH1A1HSD17B10GAA
SCHEMBL3595323 0.84 ALDH1A1 (0.44) TSHRKDM4EALDH1A1HSD17B10HPGD
SCHEMBL3589650 0.84 TSHR (0.41) TSHRKDM4EALDH1A1HSD17B10HPGD
SCHEMBL3608184 0.84 KMT2A (0.43) TSHRKDM4EALDH1A1HSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
WO-2007115231-A2 CXCR4 MODULATORS CHEMOCENTRYX, INC. (US) 2007-10-11 WO disclosed
WO-2007115231-A2 CXCR4 MODULATORS CHEMOCENTRYX, INC. (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275965-A1 CXCR4 modulators CXCL12, CXCR4, CXCR1 TSHR 1277/4885KDM4E 4801/4885ALDH1A1 662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.